-
公开(公告)号：US20210017261A1
公开(公告)日：2021-01-21
申请号：US16919032
申请日：2020-07-01
Applicant: AMGEN INC.
Inventor： Neeraj Jagdish AGRAWAL , Irwin CHEN , Su CHONG , Bryna FUCHSLOCHER , Kevin GRAHAM , Agnes Eva HAMBURGER , Mark Leo MICHAELS , Christopher MOHR , Derek E. PIPER , Kenneth William WALKER , Zhulun WANG , Cen XU
Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
-
公开(公告)号：US20170002079A1
公开(公告)日：2017-01-05
申请号：US15178652
申请日：2016-06-10
Applicant: Amgen Inc.
Inventor： Dirk E. SMITH , Ian FOLTZ , Chadwick T. KING , Ai Ching LIM , Rutilio CLARK , Michael R. COMEAU , Randal R. KETCHEM , Donghui SHI , Xiaoshan MIN , Zhulun WANG
IPC: C07K16/28
CPC classification number: C07K16/2866 , A61K2039/505 , C07K16/244 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N15/11
Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.
Abstract translation: 本文描述的是与抗原结合蛋白相关的组合物和方法，其结合人ST2，包括抗体。 在具体实施方案中，本公开提供完全人抗-ST2抗体及其衍生物及其变体。 还提供了编码这种抗体和抗体片段，变体和衍生物的核酸。 此外，提供制备和使用这些抗体的方法，包括治疗和预防自身免疫性和炎症性疾病的方法。
-
公开(公告)号：US20160168213A1
公开(公告)日：2016-06-16
申请号：US14908459
申请日：2014-07-31
Applicant: AMGEN INC.
Inventor： Yumei XIONG , Yi ZHANG , Jackie Z. SHENG , Agnes Eva HAMBURGER , Murielle VENIANT-ELLISON , Grant SHIMAMOTO , Xiaoshan MIN , Zhulun WANG , Jie TANG , Gunasekaran KANNAN , Marissa MOCK , Kenneth WALKER
IPC: C07K14/475
CPC classification number: C07K14/475 , C07K2319/30
Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
Abstract translation: 提供了包含GDF15的构建体及其突变体。 在各种实施方案中，包含GDF15及其突变体的构建体可用于治疗或改善代谢紊乱。 在各种实施方案中，代谢疾病或病症是2型糖尿病，肥胖症，血脂异常，升高的葡萄糖水平，升高的胰岛素水平和糖尿病性肾病。
-
公开(公告)号：US20150344583A1
公开(公告)日：2015-12-03
申请号：US14649469
申请日：2013-12-05
Applicant: AMGEN INC.
Inventor： Richard J. ARMITAGE , Michelle BLAKE , William C. FANSLOW, III , Jason Charles O'NEILL , Gunasekaran KANNAN , Jiangchun XU , Mark Edward TOMETSKO , Zhulun WANG , Athena SUDOM
CPC classification number: C07K16/2878 , A61K45/06 , A61K47/6803 , A61K47/6849 , A61K2039/505 , A61N5/10 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94
Abstract: The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates and uses thereof.
Abstract translation: 本发明涉及BCMA（B细胞成熟抗原）抗原结合蛋白，例如抗体，编码所述抗原结合蛋白的多核苷酸序列，以及用于诊断和治疗疾病的组合物和方法。 本发明还涉及BCMA抗体药物共轭物及其用途。
-
公开(公告)号：US20240368236A1
公开(公告)日：2024-11-07
申请号：US18639202
申请日：2024-04-18
Applicant: Amgen Inc.
Inventor： Yumei XIONG , Yi ZHANG , Jackie Z. SHENG , Agnes Eva HAMBURGER , Murielle M. VENIANT-ELLISON , Grant SHIMAMOTO , Xiaoshan MIN , Zhulun WANG , Jie TANG , Gunasekaran KANNAN , Marissa MOCK , Kenneth William WALKER
IPC: C07K14/475
Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
-
Patent Agency Ranking
16.发明公开公开(公告)号：US20240182600A1
公开(公告)日：2024-06-06
申请号：US18556248
申请日：2022-04-19
Applicant: AMGEN INC.
Inventor： Danyang GONG , Bram ESTES , Zhulun WANG , Fernando GARCES
IPC: C07K16/46
CPC classification number: C07K16/468 , C07K2317/31 , C07K2317/526
Abstract: The clinical potential of multispecific antibodies like bispecific and trispecific antibodies shows great promise for targeting complex diseases. However, the generation of those molecules presents great challenges particularly in regard to achieving acceptable expression levels free from mis-paired polypeptides. The presently claimed invention is directed to multispecific antigen binding proteins which improve upon existing charge pair technologies by redistributing the engineered charges within the CH3 regions of a heteromultimer.
-
公开(公告)号：US20230381276A1
公开(公告)日：2023-11-30
申请号：US18072959
申请日：2022-12-01
Applicant: AMGEN INC.
Inventor： Khaled M.K.Z. ALI , Neeraj Jagdish AGRAWAL , Gunasekaran KANNAN , Ian FOLTZ , Zhulun WANG , Darren BATES , Marissa MOCK , Shunsuke TAKENAKA
CPC classification number: A61K38/20 , C12N15/63 , A61P35/00 , C07K16/283 , C07K14/54 , A61K47/6849 , A61K47/6813 , C12N2740/10041
Abstract: Provided herein are IL-21 muteins and fusion proteins comprising the same for use in methods of treating a disease. Related conjugates, nucleic acids, vectors, host cells, pharmaceutical compositions and kits are also provided herein. Methods of making the IL-21 muteins and fusion proteins comprising the same, as well as methods of treating a subject in need thereof, are provided by the present disclosure. Further provided are PD-1 antigen-binding proteins.
-
公开(公告)号：US20220235148A1
公开(公告)日：2022-07-28
申请号：US17615555
申请日：2020-05-29
Applicant: Amgen Inc.
Inventor： Fernando GARCES , Zhulun WANG
Abstract: The clinical potential of multispecific antibodies like bispecific and trispecific antibodies shows great promise for targeting complex diseases. However, the generation of those molecules presents great challenges as in many cases it is desired to specifically drive the specific pairing of multiple polypeptide chains that are present in solutions. In the case of the heavy chains, there are two main regions that form a dimer interface. One of them is the CH3 region, which has been widely exploited by inserting either charge-pair mutations (CPMs) to steer the dimer interface or inserting large bulky residues into cavities (Knob in Hole) to physically favor and disfavor the dimer formation. However, each of these strategies may not be applied to every molecule and therefore there is the need for more tools. Here, we describe the engineering of the Hinge region with a small number of mutations that are capable to alone successfully drive the heavy chain dimerization.
-
公开(公告)号：US20190218279A1
公开(公告)日：2019-07-18
申请号：US16246326
申请日：2019-01-11
Applicant: AMGEN INC.
Inventor： Neeraj Jagdish AGRAWAL , Irwin CHEN , Su CHONG , Bryna FUCHSLOCHER , Kevin GRAHAM , Agnes Eva HAMBURGER , Mark Leo MICHAELS , Christopher MOHR , Derek E. PIPER , Kenneth William WALKER , Zhulun WANG , Cen XU
Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
-
公开(公告)号：US20180079790A1
公开(公告)日：2018-03-22
申请号：US15826442
申请日：2017-11-29
Applicant: Amgen Inc.
Inventor： Yumei XIONG , Yi ZHANG , Jackie Z. SHENG , Agnes Eva HAMBURGER , Murielle M. VENIANT-ELLISON , Grant SHIMAMOTO , Xiaoshan MIN , Zhulun WANG , Jie TANG , Gunasekaran KANNAN , Marissa MOCK , Kenneth William WALKER
IPC: C07K14/475
CPC classification number: C07K14/475 , C07K2319/30
Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
-
-
-
-
-
-
-
-
-
Search Results
31
records
(took 0.031 seconds)
